ΨΥΧΟΛΟΓΙΑ - Έρευνα και Εφαρμογές ΤΕΥΧΟΣ 4ο | Page 71

ΙSSN: 2623- 3673
Φεβρουάριος, 2019
Ψυχολογία :έρευνα & εφαρμογές
77. Malla A, Mustafa S, Rho A, Abadi S, Lepage M, Joober R. Therapeutic
effectiveness and tolerability of aripiprazole as initial choice of treatment in first
episode psychosis in an early intervention service: A one-year outcome study.
78. Cooper S, Reynolds G. J Psychopharmacol. 2016 Aug;30(8):717-48. BAP
guidelines on the management of weight gain, metabolic disturbances and
cardiovascular risk associated with psychosis and antipsychotic drug treatment.
79. Barnes T, England E, Haddad P, Heald A, Holt R, Lingford-Hughes A,
Osborn D, McGowan O, Patel M, Paton C, Reid P, Shiers D, Smith J. J Clin
Psychopharmacol. 2016 Jun;36(3):206-12. Paliperidone Palmitate and Metabolic
Syndrome in Patients With Schizophrenia: A 12-Month Observational
Prospective Cohort Study.
Rosso G1, Pessina E, Martini A, Di Salvo G, Maina G.
80. Yang L, Chen J, Li Y, Wang Y, Liang S, Shi Y, Shi S, Xu Y.World J Biol
Psychiatry. 2016 Sep;17(6):467-74. Association between SCAP and SREBF1
gene polymorphisms and metabolic syndrome in schizophrenia patients treated
with atypical antipsychotics.
81. Lian J, Huang X, Pai N, Deng C. Pharmacol Res. 2016 Apr;106:51-63.
Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and
clinical implications.
82. Jantschak F, Brosda J, Franke R, Fink H, Möller D, Hübner H, Gmeiner P,
Pertz H. J Pharmacol Exp Ther. 2013 Oct;347(1):57-68 Pharmacological profile
of 2-bromoterguride at human dopamine D2, porcine serotonin 5-
hydroxytryptamine 2A, and α2C-adrenergic receptors, and its antipsychotic-like
effects in rats.
83. Hashimoto K, Sugawara N, Ishioka M, Nakamura K, Yasui-Furukori N.
Neuropsychiatr Dis Treat. 2014 Aug 22;10:1571-6. The effects of additional
treatment with terguride, a partial dopamine agonist, on hyperprolactinemia
induced by antipsychotics in schizophrenia patients: a preliminary study.
84. PDF The IDF worldwide defi nition of the metabolic syndrome
85. Rakesh M. Parikh and Viswanathan Mohan Indian J Endocrinol Metab. 2012
Jan-Feb; 16(1): 7–12.Changing definitions of metabolic syndrome
86. Apilak Worachartcheewan, Nalini Schaduangrat, Virapong Prachayasittikul
and Chanin Nantasenamat EXCLI J. 2018; 17: 72–88. Data mining for the
identification of metabolic syndrome status .
87. Marc De Hert Vincent Schreurs Davy Vancampfort Ruud Van Winkel
Metabolic syndrome in people with schizophrenia: a review
88. Χρήστος Θελερiτης MD, PhD, ΕΓΚΕΦΑΛΟΣ 53, 62-66, 2016 Μεταβολικές
διαταραχές μετά την λήψη άτυπων αντιψυχωσικών φαρμάκων.
89. The IDF consensus worldwide definition of the metabolic syndrome,
International Diabetes Federation, 2006.
90. Supreeya Swarup; Roman Zeltser. Last Update: October 3, 2018.Metabolic
Syndrome
91. Γρηγόριος Ν. Καρακατσούλης , περ. "ΨΥΧΟΛΟΓΙΑ έρευνα και εφαρμογές"
Γ’ Τεύχος, Αυγ. 2018. Η αποτελεσματικότητα της μελατονίνης και των
αγωνιστών της στην αντιμετώπιση των μεταβολικών ανεπιθύμητων ενεργειών
των αντιψυχωσικών δεύτερης γενεάς.